Drug reference

Haemophilus influenzae type b with meningococcal group C vaccine

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1405, 1406

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Vaccines Booster dose (for infants who have received primary immunisation with a vaccine containing Haemophilus influenzae type b component) and primary immunisation against Neisseria meningitidis ▶BY INTRAMUSCULAR INJECTION ▶Child 12–13 months: 0.5 mL for 1 dose Immunisation against Neisseria meningitidis in an unimmunised patient ▶BY INTRAMUSCULAR INJECTION ▶Child 1–9 years: 0.5 mL for 1 dose Booster dose (for children who have not been immunised against Haemophilus influenza type b) | Booster dose after recovery from Haemophilus influenzae type b disease (for index cases previously vaccinated, with low Hib antibody concentration or if it is not possible to measure antibody concentration) ▶BY INTRAMUSCULAR INJECTION ▶Child 1–9 years: 0.5 mL for 1 dose Booster dose after recovery from Haemophilus influenzae type b disease (for fully vaccinated index cases with asplenia or splenic dysfunction, if previous dose received over 1 year ago) ▶BY INTRAMUSCULAR INJECTION ▶Child 1–17 years: 0.5 mL for 1 dose ▶Adult: 0.5 mL for 1 dose Booster dose (for patients diagnosed with asplenia, splenic dysfunction or complement deficiency at under 2 years of age) ▶BY INTRAMUSCULAR INJECTION ▶Child 2–17 years: 0.5 mL for 1 dose, this booster dose should be given after the second birthday, this is the second dose of haemophilus inﬂuenzae type B vaccine combined with meningococcal group C conjugate vaccine (the ﬁrst dose is given during the routine immunisation schedule) Booster dose (for patients diagnosed with asplenia, splenic dysfunction or complement deficiency at over 2 years of age) ▶BY INTRAMUSCULAR INJECTION ▶Child 2–17 years: 0.5 mL for 1 dose, this booster dose should be followed 2 months later by one dose of meningococcal A, C, W135, and Y conjugate vaccine (in patients from 11 years of age, this interval can be reduced to one month) ▶Adult: 0.5 mL for 1 dose, this booster dose should be followed 1 month later by one dose of meningococcal A, C, W135, and Y conjugate vaccine l UNLICENSED USE Not licensed for use in patients over 2 years.

PDF page 1405

Prescribing And Dispensing Information

Available as part of the childhood immunisation schedule from ImmForm.

PDF page 1406

Safety

Side Effects

▶Common or very common Drowsiness ▶Uncommon Crying ▶Rare or very rare Abdominal pain. insomnia ▶Frequency not known Febrile seizure. meningism (but no evidence that vaccine causes meningococcal C meningitis) . muscle tone decreased

PDF page 1406

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Powder and solvent for solution for injection ▶Menitorix (GlaxoSmithKline UK Ltd) Menitorix vaccine powder and solvent for solution for injection 0.5ml vials | 1 vial P £37.76 DT = £37.76 eiiii F 1379

PDF page 1406

Dose text by age group

Child 12–13 months

0.5 mL for 1 dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1405

Child 1–9 years

0.5 mL for 1 dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1405

Child 1–9 years

0.5 mL for 1 dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1405

Child 1–17 years

0.5 mL for 1 dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1405

Adult

0.5 mL for 1 dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1405

Child 2–17 years

0.5 mL for 1 dose, this booster dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1405

Child 2–17 years

0.5 mL for 1 dose, this booster dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1405

Adult

0.5 mL for 1 dose, this booster dose should be

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1405

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Haemophilus influenzae type b with meningococcal group C vaccine

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1405, 1406

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 1405

Prescribing And Dispensing Information

Available as part of the childhood immunisation schedule from ImmForm.

PDF page 1406

Safety

Side Effects

PDF page 1406

Dose and formulations

Medicinal Forms

PDF page 1406

Dose text by age group

Child 12–13 months

0.5 mL for 1 dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1405

Child 1–9 years

0.5 mL for 1 dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1405

Child 1–9 years

0.5 mL for 1 dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1405

Child 1–17 years

0.5 mL for 1 dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1405

Adult

0.5 mL for 1 dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1405

Child 2–17 years

0.5 mL for 1 dose, this booster dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1405

Child 2–17 years

0.5 mL for 1 dose, this booster dose

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1405

Adult

0.5 mL for 1 dose, this booster dose should be

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1405

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.